Food and Environmental Research Group (SAMA-UV), Department of Preventive Medicine, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, Burjassot 46100, València, Spain.
Food and Environmental Research Group (SAMA-UV), Department of Preventive Medicine, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, Burjassot 46100, València, Spain.
Eur J Pharmacol. 2016 May 15;779:8-21. doi: 10.1016/j.ejphar.2016.02.053. Epub 2016 Feb 26.
Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopausal women (PMW), paying particular attention to long-term treatments.
自 20 世纪 80 年代中期以来，由于相关骨折，绝经后骨质疏松症（PMO）已被视为严重的公共健康问题。不断开发和正在开发能够通过增加骨量有效减少骨折数量的药物治疗方法。大多数现有药物通过减少骨吸收来抑制骨丢失，但新兴疗法可能通过刺激骨形成来增加骨量。此外，如今，最具代表性的药物已被规定足够长的时间以包括一些不良反应的报告。本综述讨论了已批准或正在研究用于治疗绝经后妇女（PMW）的骨质疏松症药物，特别关注长期治疗。
